Загрузка...
Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thromboc...
Сохранить в:
| Опубликовано в: : | Br J Haematol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6282556/ https://ncbi.nlm.nih.gov/pubmed/30191972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15573 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|